Study summary · research use only
Current neuroprotective agents in stroke
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses neuroprotective agents used in stroke patients (human), focusing on citicoline, cerebrolysin, and MLC901 (NeuroAiD II), described as having recently become more frequently used in neurorehabilitation clinics. The authors note ongoing debate over which agent to use in neurorehabilitation following acute ischemic stroke, in terms of both outcomes and safety considerations, and frame neuroprotection's goal as inhibiting neuronal death and slowing neuronal loss to reduce mortality and disability and improve quality of life.
Abstract
What is expected from neuroprotection is to inhibit neuronal death and halt or decelerate the neuronal loss to lower the mortality rates, decrease disability, and improve the quality of life following an acute ischemic stroke. Several agents were described as neuroprotective up to date; however, there is still debate which to use in the neurorehabilitation of stroke patients, in terms of both efficacy and also safety. In this review, we discuss the agents, citicoline, cerebrolysin and MLC901 (NeuroAiD II), the three agents which have started to be used frequently in neurorehabilitation clinics recently in the light of the current literature.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.